Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Arena Pharmaceuticals Inc. (ARNA), the maker of weight-loss drug Belviq, is looking for partners to sell the medicine abroad once it clears regulatory hurdles, Jack Lief, Arena?s president and chief executive officer, said.
Belviq, approved in the U.S. in June as the first new obesity drug in 13 years, is being promoted in North America by Tokyo-based Eisai Co. (4523) Lief said San Diego-based Arena is in talks with other companies to promote the therapy in Europe if it gains clearance there, with a decision expected in the first half of this year.
?Europe is not partnered yet -- we?re waiting for approval,? Lief said in an interview at the annual health-care conference sponsored by JPMorgan Chase & Co. (JPM) in San Francisco. ?We?re talking to partners presently, even at this meeting.?
http://www.bloomberg.com/news/2013-01-07/arena-seeks-partners-in-europe-china-for-obesity-drug.html
Belviq, approved in the U.S. in June as the first new obesity drug in 13 years, is being promoted in North America by Tokyo-based Eisai Co. (4523) Lief said San Diego-based Arena is in talks with other companies to promote the therapy in Europe if it gains clearance there, with a decision expected in the first half of this year.
?Europe is not partnered yet -- we?re waiting for approval,? Lief said in an interview at the annual health-care conference sponsored by JPMorgan Chase & Co. (JPM) in San Francisco. ?We?re talking to partners presently, even at this meeting.?
http://www.bloomberg.com/news/2013-01-07/arena-seeks-partners-in-europe-china-for-obesity-drug.html